Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Thanh Truong Giang Ly; Jisoo Yun; Jong Seong Ha; Yeon Ju Kim; Woong Bi Jang; Thi Hong Van Le; Vinoth Kumar Rethineswaran; Jaewoo Choi; Jae Ho Kim; Sang Hyun Min; Dong Hyung Lee; Ju Seok Yang; Joo Seop Chung; Sang Mo Kwon

doi:10.3390/ijms23020944

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Thanh Truong Giang Ly, Jisoo Yun, Jong Seong Ha, Yeon Ju Kim, Woong Bi Jang, Thi Hong Van Le, Vinoth Kumar Rethineswaran, Jaewoo Choi, Jae Ho Kim, Sang Hyun Min, Dong Hyung Lee, Ju Seok Yang, Joo Seop Chung, Sang Mo Kwon

Department of Innovative Pharmaceutical Sciences

Pusan National University

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via au-tophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.

Original language	English
Article number	944
Journal	International Journal of Molecular Sciences
Volume	23
Issue number	2
DOIs	https://doi.org/10.3390/ijms23020944
State	Published - 1 Jan 2022

Keywords

AGR2
Autophagy
Etravirine
Ovarian cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms23020944

Cite this

Ly, T. T. G., Yun, J., Ha, J. S., Kim, Y. J., Jang, W. B., Van Le, T. H., Rethineswaran, V. K., Choi, J., Kim, J. H., Min, S. H., Lee, D. H., Yang, J. S., Chung, J. S., & Kwon, S. M. (2022). Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis. International Journal of Molecular Sciences, 23(2), Article 944. https://doi.org/10.3390/ijms23020944

@article{a90e17a65592492d83db2312a1ccfd45,

title = "Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis",

abstract = "Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via au-tophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.",

keywords = "AGR2, Autophagy, Etravirine, Ovarian cancer",

author = "Ly, {Thanh Truong Giang} and Jisoo Yun and Ha, {Jong Seong} and Kim, {Yeon Ju} and Jang, {Woong Bi} and {Van Le}, {Thi Hong} and Rethineswaran, {Vinoth Kumar} and Jaewoo Choi and Kim, {Jae Ho} and Min, {Sang Hyun} and Lee, {Dong Hyung} and Yang, {Ju Seok} and Chung, {Joo Seop} and Kwon, {Sang Mo}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

day = "1",

doi = "10.3390/ijms23020944",

language = "English",

volume = "23",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "2",

}

Ly, TTG, Yun, J, Ha, JS, Kim, YJ, Jang, WB, Van Le, TH, Rethineswaran, VK, Choi, J, Kim, JH, Min, SH, Lee, DH, Yang, JS, Chung, JS & Kwon, SM 2022, 'Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis', International Journal of Molecular Sciences, vol. 23, no. 2, 944. https://doi.org/10.3390/ijms23020944

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis. / Ly, Thanh Truong Giang; Yun, Jisoo; Ha, Jong Seong et al.
In: International Journal of Molecular Sciences, Vol. 23, No. 2, 944, 01.01.2022.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

AU - Ly, Thanh Truong Giang

AU - Yun, Jisoo

AU - Ha, Jong Seong

AU - Kim, Yeon Ju

AU - Jang, Woong Bi

AU - Van Le, Thi Hong

AU - Rethineswaran, Vinoth Kumar

AU - Choi, Jaewoo

AU - Kim, Jae Ho

AU - Min, Sang Hyun

AU - Lee, Dong Hyung

AU - Yang, Ju Seok

AU - Chung, Joo Seop

AU - Kwon, Sang Mo

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via au-tophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.

AB - Anterior gradient protein 2 homolog (AGR2), an endoplasmic reticulum protein, is secreted in the tumor microenvironment. AGR2 is a member of the disulfide isomerase family, is highly expressed in multiple cancers, and promotes cancer metastasis. In this study, we found that etravirine, which is a non-nucleoside reverse transcriptase inhibitor, could induce AGR2 degradation via au-tophagy. Moreover, etravirine diminished proliferation, migration, and invasion in vitro. Moreover, in an orthotopic xenograft mouse model, the combination of etravirine and paclitaxel significantly suppressed cancer progression and metastasis. This drug may be a promising therapeutic agent for the treatment of ovarian cancer.

KW - AGR2

KW - Autophagy

KW - Etravirine

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85122783225&partnerID=8YFLogxK

U2 - 10.3390/ijms23020944

DO - 10.3390/ijms23020944

M3 - Article

C2 - 35055132

AN - SCOPUS:85122783225

SN - 1661-6596

VL - 23

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 2

M1 - 944

ER -

Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this